About Sectoral
Sectoral is a venture capital firm founded in 2000. It is primarily based out of Montreal, Canada. As of Sep 2026, Sectoral is an active investor, having invested in 45 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series C round of HighLife Medical Overall, Sectoral portfolio has seen 15 IPOs and 14 acquisitions including key companies like Regenxbio, Ascendis Pharma and Apellis Pharmaceuticals. A lot of funds co-invest with Sectoral, with names like Janus Henderson Investors sharing a substantial percentage of its portfolio. Sectoral has team of 8 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 5 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Sectoral's List of Top Investments
Sectoral has a portfolio of 45 companies. Their most notable investments are in Phagenesis and Cogent Biosciences.Their portfolio spans across United States, Canada, France and 5 more locations. They have invested in Life Sciences, High Tech, HealthTech and 1 other sectors, across stages such as Series B, Series C and 5 more. Here is the list of top investments by Sectoral:1. Regenxbio
Developer of AAV Gene Therapy for rare genetic diseases. The company's proprietary AAV gene delivery platform (NAV Technology Platform) which is used for the development of candidates includes programs for the treatment of two severe and rare genetic diseases, homozygous familial hypercholesterolemia (HoFH) and Mucopolysaccharidosis Type I (MPS I). Also, developing candidates for liver, neurological, and retinal diseases.
Key facts about Regenxbio
- Founded Year: 2008
- Location: Rockville (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $108M
- Employee Count: 390 as on Sep 30, 2026
- Investors: RTW Investments, Brookside Capital and 15 Others
- Latest Funding Round: Grant (prize money), Sep 15, 2020, $*****
- Highlight: Public
Ascendis Pharma develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension. Also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection for the treatment of Age-related Macular Edema (AMD). It has strategic collaborations with Sanofi and Genentech.
Key facts about Ascendis Pharma
- Founded Year: 2007
- Location: Hellerup (Denmark)
- Stage: Public
- Total Funding till date: $109M
- Employee Count: 1,460 as on Sep 30, 2026
- Investors: Gilde Healthcare, Venrock and 15 Others
- Latest Funding Round: Series D, Nov 24, 2014, $*****
- Highlight: Public
Developer of therapeutics for the treatment of rare diseases. The company is developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. The company develops programs across ophthalmology, nephrology, hematology, and neurology.
Key facts about Apellis Pharmaceuticals
- Founded Year: 2008
- Location: Crestwood (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $213M
- Employee Count: 518 as on Sep 30, 2026
- Investors: Avoro Capital, VenBio and 21 Others
- Latest Funding Round: Post IPO, May 07, 2020, $*****
- Highlight: Acquired
Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases. The company has developed therapies in which cells are modified genetically and returned to the patient, including regulation of chimeric antigen receptors on T cells (CAR-T) and checkpoint inhibitors. The initial therapeutic focus is ex vivo applications which include blood disorders, therapeutic protein production, and cancer. The company's lead candidate NTLA-2002, is an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema.
Key facts about Intellia Therapeutics
- Founded Year: 2014
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $85M
- Employee Count: 521 as on Sep 30, 2026
- Investors: Atlas Venture, Foresite Capital and 10 Others
- Latest Funding Round: Series B, Sep 01, 2015, $*****
- Highlight: Public
5. Evommune
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Key facts about Evommune
- Founded Year: 2020
- Location: Sacramento (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $276M
- Employee Count: 69 as on Aug 31, 2026
- Investors: RTW Investments, Marshall Wace and 18 Others
- Latest Funding Round: Post IPO, Feb 12, 2026, $*****
- Highlight: Public
Sectoral's Year-on-Year Investment Trends
Sectoral has invested in 45 companies over the last 17 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 3 investments, while as of Sep 2026, it has made 2 investments in this year. Its most recent first time investment was in Route 92 Medical and most recent follow-on round was in HighLife Medical.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 2 | 1 | 3 |
2024 | 3 | 2 | 5 |
2023 | 3 | 3 | 6 |
2022 | 4 | 1 | 5 |
2021 | 5 | 1 | 6 |
2020 | 6 | 0 | 6 |
2019 | 1 | 0 | 1 |
2018 | 1 | 2 | 3 |
2017 | 3 | 0 | 3 |
Sectoral's Investments by Stage
Sectoral has made 15 investments in Series B stage with an average round size of $45.3M, 8 investments in Series C stage with an average round size of $68.4M and 7 investments in Series D stage with an average round size of $83.8M.Stage of entry | No. of Investments |
|---|---|
Series B | 15 |
Series C | 8 |
Series D | 7 |
Series A | 4 |
Post IPO | 3 |
Others | 5 |
Note: We have considered here, only first round of investments
Sectoral's Investments by Sector
Sectoral has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Sustainability Tech. Notably, it has invested in 45 Tech companies, 39 Enterprise (B2B) companies, 7 Tech hardware companies and 6 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 40 |
High Tech | 4 |
Enterprise Applications | 2 |
HealthTech | 2 |
Sustainability Tech | 2 |
Note: We have considered here, only first round of investments
Sectoral's Investments by Geography
Sectoral has made most investments in United States (33), followed by Canada where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 33 |
Canada | 2 |
France | 2 |
United Kingdom | 2 |
Denmark | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Sectoral's recent investments
Sectoral has made 2 investments in 2026 so far - HighLife Medical and Route 92 Medical.Here are the most recent investments by Sectoral:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 22, 2026 | France | Series C | 3610 | [+11] | |
Jan 13, 2026 | United States | Series F | 3850 | [+4] | |
Oct 22, 2025 | United States | Series A | 7404 | [+2] | |
Aug 19, 2025 | United States | Series C | 7428 | [+4] | |
Mar 06, 2025 | United States | Series E | 4828 | [+4] |
IPOs and Publicly Listed companies in Sectoral's Portfolio
15 of Sectoral's portfolio companies have become public. Apnimed got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2026 at marketcap of $637M and Evommune got listed on the New York Stock Exchange (NYSE) at marketcap of $481M.Here are Sectoral's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 31, 2026 | Apr 28, 2022 | Series C | 5996 | |
Nov 06, 2025 | Oct 30, 2024 | Series C | 8915 | |
Jul 31, 2025 | Mar 06, 2025 | Series E | 9104 | |
Apr 05, 2024 | - | - | 1180 | |
Mar 28, 2024 | May 16, 2023 | Series C | 6241 |
_1568982092325.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in Sectoral's Portfolio
14 companies from Sectoral's portfolio have been acquired. The most recent acquisition was Noctrix Health in Apr 2026 by ResMed for $*****.Here are Sectoral's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 30, 2026 | Jan 16, 2024 | Series C | 2438 | |
Mar 31, 2026 | Aug 14, 2017 | Series E | 8950 | |
Jun 27, 2025 | Jun 29, 2021 | Series D | 3394 | |
Apr 05, 2024 | May 19, 2015 | Series B | 4767 | |
Mar 14, 2024 | Sep 16, 2021 | Series B | 7261 |
Team profile of Sectoral
Sectoral has a team of 8 members including 4 Partners and 1 Principal located in Canada, China and 1 more location. Sectoral's team does not sit on the board of any company as of now.Here is a list of all team members in Sectoral:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Montreal | - | - | |
Partner | Geneva | - | - | |
Partner | Montreal | - | - | |
Partner | Hong Kong | - | - | |
Principal | Montreal | - | - |
Co-investors of Sectoral
Over the past 17 years, 355 investors have co-invested in Sectoral's portfolio companies. This includes funds and angels.
- Invested before Sectoral: HHS, F-Prime Capital and 153 others have invested in rounds before Sectoral. There are 5 companies where HHS has invested before Sectoral and 4 companies where F-Prime Capital has invested before Sectoral.
- Top Co-investors of Sectoral: 128 investors entered a company along with Sectoral. These include investors like Janus Henderson Investors (7 companies).
- Invested after Sectoral: A total of 72 investors have invested in Sectoral's portfolio after their investments. Top Investors include EQT (3 companies), SV Health Investors (2 companies) and Redmile Group (2 companies).
Recent News related to Sectoral
•
Route 92 Medical Receives $50M in Growth FinancingFinSMEs•Apr 07, 2026•Norwest, Route 92 Medical, Sectoral, InnovaHealth Partners and 3 others
•
•
SecondWave Systems Secures New Investor to Expand Series A for Anti-Inflammatory TreatmentPR Newswire•Oct 22, 2025•SecondWave Systems, Sectoral, Treo Ventures, Scientific Health Development and 1 other
•
AP Iantrek Secures $42M Series C for AlloFlo™ Uveo Launch and Pipeline ExpansionBakersfield•Aug 20, 2025•Iantrek, Sectoral, Visionary Ventures, Civilization Ventures and 3 others
•
Shoulder Innovations Announces Closing of $40 Million Series E Equity Financingintelligence360•Mar 14, 2025•Shoulder Innovations, Usventure, Sectoral, Arboretum Ventures and 3 others
•
Shoulder Innovations Closes $40M in Series E Equity FinancingFinSMEs•Mar 10, 2025•Shoulder Innovations, USVP, Gilde Healthcare, Gilmartin Capital and 3 others
•
Evommune raises $115M to accelerate immune drug testsBioPharmaDive•Oct 31, 2024•Evommune, RA Capital Management, Sectoral, B Capital and 14 others
•
Phagenesis Appoints Chad Hoskins as Chief Executive Officer Following Recent Close of $42M Series D FinancingPR Newswire•Sep 05, 2024•Phagenesis, EQT, Sectoral, British Patient Capital and 3 others
•
Miach Orthopaedics Raises $20 Million in Series B ExtensionOrthoSpineNews•Apr 02, 2024•Miach Orthopaedics, MLSPA, SV Health Investors, Aperture Venture Partners and 6 others
•
